KR101928225B1 - Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염 - Google Patents

Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염 Download PDF

Info

Publication number
KR101928225B1
KR101928225B1 KR1020177000573A KR20177000573A KR101928225B1 KR 101928225 B1 KR101928225 B1 KR 101928225B1 KR 1020177000573 A KR1020177000573 A KR 1020177000573A KR 20177000573 A KR20177000573 A KR 20177000573A KR 101928225 B1 KR101928225 B1 KR 101928225B1
Authority
KR
South Korea
Prior art keywords
cyt
pyrimidin
cyanomethyl
morpholinophenylamino
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000573A
Other languages
English (en)
Korean (ko)
Other versions
KR20170015496A (ko
Inventor
브랜든 에이치. 브라운
어니스트 에이. 카라
제프리 엔. 헤멘웨이
헨리 모리슨
트로이 레이놀즈
빙 시
디미트리오스 스테파니디스
팡 왕
매튜 로버트 워르
제임스 앤드류 휘트니
얀 신
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101928225(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20170015496A publication Critical patent/KR20170015496A/ko
Application granted granted Critical
Publication of KR101928225B1 publication Critical patent/KR101928225B1/ko
Assigned to 글락소스미스클라인 엘엘씨 reassignment 글락소스미스클라인 엘엘씨 권리의 전부이전등록 Assignors: 길리애드 사이언시즈, 인코포레이티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177000573A 2014-06-12 2015-06-11 Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염 Active KR101928225B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
US62/011,315 2014-06-12
PCT/US2015/035316 WO2015191846A1 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Publications (2)

Publication Number Publication Date
KR20170015496A KR20170015496A (ko) 2017-02-08
KR101928225B1 true KR101928225B1 (ko) 2018-12-11

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000573A Active KR101928225B1 (ko) 2014-06-12 2015-06-11 Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염

Country Status (36)

Country Link
US (5) US9469613B2 (https=)
EP (3) EP3154950B1 (https=)
JP (5) JP6600649B2 (https=)
KR (1) KR101928225B1 (https=)
CN (2) CN106458929A (https=)
AP (1) AP2016009551A0 (https=)
AR (1) AR100818A1 (https=)
AU (1) AU2015274554B9 (https=)
BR (1) BR112016028749A2 (https=)
CA (1) CA2951883C (https=)
CR (1) CR20160575A (https=)
CU (1) CU20160183A7 (https=)
CY (2) CY1123604T1 (https=)
DK (1) DK3154950T3 (https=)
EA (1) EA032639B1 (https=)
EC (1) ECSP16093323A (https=)
ES (1) ES2822773T3 (https=)
FI (1) FIC20240025I1 (https=)
FR (1) FR24C1030I2 (https=)
HR (1) HRP20201492T1 (https=)
HU (2) HUE051360T2 (https=)
IL (3) IL249038B (https=)
LT (2) LT3154950T (https=)
MA (1) MA40067A (https=)
MX (3) MX374541B (https=)
NL (1) NL301282I2 (https=)
NZ (1) NZ725966A (https=)
PH (1) PH12016502461A1 (https=)
PL (1) PL3154950T3 (https=)
PT (1) PT3154950T (https=)
RS (1) RS61065B1 (https=)
SG (2) SG11201610079VA (https=)
SI (1) SI3154950T1 (https=)
TW (3) TWI729644B (https=)
UY (1) UY36166A (https=)
WO (1) WO2015191846A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
KR20210047308A (ko) 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN117794545A (zh) 2021-07-30 2024-03-29 葛兰素史密斯克莱有限责任公司 骨髓纤维化的治疗中的生物标志物和患者选择
EP4384181A2 (en) 2021-08-10 2024-06-19 GlaxoSmithKline LLC Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041789A1 (en) 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2008109943A1 (en) 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2010017122A2 (en) 2008-08-05 2010-02-11 Targegen Inc. Methods of treating thalassemia

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2295329C2 (ru) 2001-09-12 2007-03-20 ВиРекс Медикал Корпорейшн Перекрывающее кровоток твердофазное средство с покрытием из иммобилизованного связывающего средства
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
EP1560824A1 (en) 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010141946A1 (en) 2009-06-05 2010-12-09 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
MD20130089A2 (ro) 2011-05-02 2014-05-31 Ym Biosciences Australia Pty Ltd Metodă de tratament al mielomului multiplu
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
JP2016505015A (ja) 2013-01-09 2016-02-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化モメロチニブ（ｍｏｍｅｌｏｔｉｎｉｂ）
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041789A1 (en) 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2008109943A1 (en) 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2010017122A2 (en) 2008-08-05 2010-02-11 Targegen Inc. Methods of treating thalassemia

Also Published As

Publication number Publication date
IL276948A (en) 2020-10-29
HUE051360T2 (hu) 2021-03-01
FIC20240025I1 (fi) 2024-07-12
DK3154950T3 (da) 2020-09-14
EA201692356A1 (ru) 2017-07-31
AU2015274554B2 (en) 2018-02-15
JP2018184486A (ja) 2018-11-22
TWI681954B (zh) 2020-01-11
JP7198867B2 (ja) 2023-01-04
CN106458929A (zh) 2017-02-22
ES2822773T3 (es) 2021-05-04
NZ725966A (en) 2018-04-27
JP6840909B2 (ja) 2021-03-10
EP3154950A1 (en) 2017-04-19
TW202012378A (zh) 2020-04-01
FR24C1030I1 (fr) 2024-08-30
JP6600649B2 (ja) 2019-10-30
IL276948B (en) 2021-09-30
IL286442A (en) 2021-10-31
CR20160575A (es) 2017-01-20
AP2016009551A0 (en) 2016-11-30
MA40067A (fr) 2015-12-17
US20150361050A1 (en) 2015-12-17
TW202134236A (zh) 2021-09-16
MX2022015558A (es) 2023-01-30
TW201617323A (zh) 2016-05-16
CA2951883A1 (en) 2015-12-17
IL249038B (en) 2020-09-30
CY2024024I1 (el) 2025-03-28
USRE49445E1 (en) 2023-03-07
EP3907219A1 (en) 2021-11-10
CU20160183A7 (es) 2017-05-10
CA2951883C (en) 2020-05-05
USRE50497E1 (en) 2025-07-22
PL3154950T3 (pl) 2021-01-25
MX2016016294A (es) 2017-09-01
ECSP16093323A (es) 2017-01-31
HUS2400025I1 (hu) 2024-08-28
LTPA2024523I1 (https=) 2024-07-25
CY1123604T1 (el) 2022-03-24
NL301282I2 (nl) 2025-03-12
SG10201911925TA (en) 2020-01-30
CN110627728A (zh) 2019-12-31
BR112016028749A2 (pt) 2017-08-22
EA032639B1 (ru) 2019-06-28
JP2021107465A (ja) 2021-07-29
WO2015191846A1 (en) 2015-12-17
SI3154950T1 (sl) 2021-01-29
AU2015274554B9 (en) 2018-04-19
EP3719005A1 (en) 2020-10-07
EP3154950B1 (en) 2020-08-05
MX374541B (es) 2025-03-06
AU2015274554A1 (en) 2016-11-24
PH12016502461A1 (en) 2017-03-06
JP6883560B2 (ja) 2021-06-09
PT3154950T (pt) 2020-10-09
AR100818A1 (es) 2016-11-02
HRP20201492T1 (hr) 2021-01-08
USRE48285E1 (en) 2020-10-27
RS61065B1 (sr) 2020-12-31
FR24C1030I2 (fr) 2025-06-13
IL249038A0 (en) 2017-01-31
JP7550205B2 (ja) 2024-09-12
TWI729644B (zh) 2021-06-01
LT3154950T (lt) 2020-11-25
JP2017517535A (ja) 2017-06-29
CY2024024I2 (el) 2025-03-28
KR20170015496A (ko) 2017-02-08
JP2020059759A (ja) 2020-04-16
US20160347719A1 (en) 2016-12-01
UY36166A (es) 2016-01-29
MX2019009564A (es) 2019-10-02
SG11201610079VA (en) 2016-12-29
US9809559B2 (en) 2017-11-07
US9469613B2 (en) 2016-10-18
JP2023021454A (ja) 2023-02-10

Similar Documents

Publication Publication Date Title
KR101928225B1 (ko) Ｎ-(시아노메틸)-4-(2-(4-모르폴리노페닐아미노)피리미딘-4-일)벤즈아미드 히드로클로라이드 염
BR112016008016B1 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditoscompostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ounras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dosditos compostos
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
BR102017019447A2 (pt) Composto, um sal farmaceuticamente aceitável, isômero ou uma mistura dos mesmos, composição farmacêutica, método para tratamento de uma doença ou condição, inibição da atividade de um polipeptídeo fosfatidilinositol 3-quinase e inibição de reações imunes excessivas ou destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero ou uma mistura dos mesmos
HK40063342A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1231079A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527B (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211124

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20221123

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 8, Claim Number : 1 3 9, Period Limitation Text : 1502, Comment Text : 304, 303, 302

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8